Preoperative chemotherapy and carbon ions therapy for treatment of resectable and borderline resectable pancreatic adenocarcinoma: a prospective, phase II, multicentre, single-arm study

Viviana Vitolo, Lorenzo Cobianchi, Silvia Brugnatelli, Amelia Barcellini, Andrea Peloso, Angelica Facoetti, Alessandro Vanoli, Sara Delfanti, Lorenzo Preda, Silvia Molinelli, Catherine Klersy, Piero Fossati, Roberto Orecchia, Francesca Valvo, Viviana Vitolo, Lorenzo Cobianchi, Silvia Brugnatelli, Amelia Barcellini, Andrea Peloso, Angelica Facoetti, Alessandro Vanoli, Sara Delfanti, Lorenzo Preda, Silvia Molinelli, Catherine Klersy, Piero Fossati, Roberto Orecchia, Francesca Valvo

Abstract

Background: Pancreatic adenocarcinoma is a high-mortality neoplasm with a documented 5-years-overall survival around 5%. In the last decades, a real breakthrough in the treatment of the disease has not been achieved. Here we propose a prospective, phase II, multicentre, single-arm study aiming to assess the efficacy and the feasibility of a therapeutic protocol combining chemotherapy, carbon ion therapy and surgery for resectable and borderline resectable pancreatic adenocarcinoma.

Method: The purpose of this trial (PIOPPO Protocol) is to assess the efficacy and the feasibility of 3 cycles of FOLFIRINOX neoadjuvant chemotherapy followed by a short-course of carbon ion radiotherapy (CIRT) for resectable or borderline resectable pancreatic adenocarcinoma patients. Primary outcome of this study is the assessment of local progression free survival (L-PFS). The calculation of sample size is based on the analysis of the primary endpoint "progression free survival" according to Fleming's Procedure.

Discussion: Very preliminary results provide initial evidence of the feasibility of the combined chemotherapy and CIRT in the neoadjuvant setting for resectable or borderline resectable pancreatic cancer. Completion of the accrual and long term results are awaited to see if this combination of treatment is advisable and will provide the expected benefits.

Trial registration: ClinicalTrials.gov Identifier: NCT03822936 registered on January 2019.

Keywords: Carbon ion radiation therapy; Chemotherapy; Pancreatic adenocarcinoma; Surgery.

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
PIOPPO trial scheme

References

    1. Gillen S, Schuster T, Meyer Zum Buschenfelde C, Friess H, Kleeff J. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med. 2010;7:e1000267. doi: 10.1371/journal.pmed.1000267.
    1. Hackert T. Surgery for pancreatic Cancer after neoadjuvant treatment. Ann Gastroenterol Surg. 2018;2(6):413–418. doi: 10.1002/ags3.12203.
    1. McGuigan A, Kelly P, Turkington RC, Jones C, Coleman HG, McCain RS. Pancreatic cancer: a review of clinical diagnosis, epidemiology, treatment and outcomes. World J Gastroenterol. 2018;24(43):4846–4861. doi: 10.3748/wjg.v24.i43.4846.
    1. Zhan HX, Xu JW, Wu D, Wu ZY, Wang L, Hu SY, Zhang GY. Neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of prospective studies. Cancer Med. 2017;6(6):1201–1219. doi: 10.1002/cam4.1071.
    1. Reni M, Balzano G, Zanon S, Zerbi A, Rimassa L, Castoldi R, Pinelli D, Mosconi S, Doglioni C, Chiaravalli M, Pircher C, Arcidiacono PG, Torri V, Maggiora P, Ceraulo D, Falconi M, Gianni L. Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a randomised, open-label, phase 2-3 trial. Lancet Gastroenterol Hepatol. 2018;3(6):413–423. doi: 10.1016/S2468-1253(18)30081-5.
    1. Yoo C, Kang J, Kim KP, Lee JL, Ryoo BY, Chang HM, Lee SS, Park DH, Song TJ, Seo DW, Lee SK, Kim MH, Park JH, Hwang DW, Song KB, Lee JH, Kim SC. Efficacy and safety of neoadjuvant FOLFIRINOX for borderline resectable pancreatic adenocarcinoma: improved efficacy compared with gemcitabine-based regimen. Oncotarget. 2017;8(28):46337–46347. doi: 10.18632/oncotarget.17940.
    1. Silvestris N, Longo V, Cellini F, Reni M, Bittoni A, Cataldo I, Partelli S, Falconi M, Scarpa A, Brunetti O, Lorusso V, Santini D, Morganti A, Valentini V, Cascinu S. Neoadjuvant multimodal treatment of pancreatic ductal adenocarcinoma. Crit Rev Oncol Hematol. 2016;98:309–324. doi: 10.1016/j.critrevonc.2015.11.016.
    1. Hosein PJ, Macintyre J, Kawamura C, Maldonado JC, Ernani V, Loaiza-Bonilla A, Narayanan G, Ribeiro A, Portelance L, Merchan JR, Levi JU, Rocha-Lima CM. A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma. BMC Cancer. 2012;12:199. doi: 10.1186/1471-2407-12-199.
    1. Blazer M, Wu C, Goldberg RM, Phillips G, Schmidt C, Muscarella P, Wuthrick E, Williams TM, Reardon J, Ellison EC, Bloomston M, Bekaii-Saab T. Neoadjuvant modified (m) FOLFIRINOX for locally advanced unresectable (LAPC) and borderlineresectable (BRPC) adenocarcinoma of the pancreas. Ann Surg Oncol. 2015;22(4):1153–1159. doi: 10.1245/s10434-014-4225-1.
    1. Tang K, Lu W, Qin W, Wu Y. Neoadjuvant therapy for patients with borderline resectable pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. Pancreatology. 2016;16(1):28–37. doi: 10.1016/j.pan.2015.11.007.
    1. Shinoto M, Yamada S, Terashima K, Yasuda S, Shioyama Y, Honda H, Kamada T, Tsujii H, Saisho H. Working Group for Pancreas Cancer. Carbon ion radiation therapy with concurrent gemcitabine for patients with locally advanced pancreatic Cancer. Int J Radiat Oncol Biol Phys. 2016;95(1):498–504. doi: 10.1016/j.ijrobp.2015.12.362.
    1. Mohamad Osama, Sishc Brock, Saha Janapriya, Pompos Arnold, Rahimi Asal, Story Michael, Davis Anthony, Kim D.W. Carbon Ion Radiotherapy: A Review of Clinical Experiences and Preclinical Research, with an Emphasis on DNA Damage/Repair. Cancers. 2017;9(12):66. doi: 10.3390/cancers9060066.
    1. Sai S, Wakai T, Vares G, et al. Combination of carbon ion beam and gemcitabine causes irreparable DNA damage and death of radioresistant pancreatic cancer stem-like cells in vitro and in vivo. Oncotarget. 2015;6(8):5517–5535. doi: 10.18632/oncotarget.3584.
    1. Tsujii H, Kamada T. A review of update clinical results of carbon ion radiotherapy. Jpn J Clin Oncol. 2012;42(8):670–685. doi: 10.1093/jjco/hys104.
    1. Shinoto M, Yamada S, Yasuda S, Imada H, Shioyama Y, Honda H, Kamada T, Tsujii H, Saisho H. Phase 1 trial of preoperative, short-course carbon-ion radiotherapy for patients with resectable pancreatic cancer. Cancer. 2013;119(1):45–51. doi: 10.1002/cncr.27723.
    1. Ebner DK, Shinoto M, Kawashiro S, Isozaki Y, Kamada T, Yamada S. Phase 1/2 trial of preoperative short-course carbon-ion radiation therapy for patients with resectable pancreatic cancer. Int J Radiat Oncol Biol Phys. 2017;99:S144. doi: 10.1016/j.ijrobp.2017.06.334.
    1. Durante M, Orecchia R, Loeffler JS. Charged-particle therapy in cancer: clinical uses and future perspectives. Nat Rev Clin Oncol. 2017;14(8):483–495. doi: 10.1038/nrclinonc.2017.30.
    1. Ebner DK, Kamada T. The emerging role of carbon-ion radiotherapy. Front Oncol. 2016;6:140. doi: 10.3389/fonc.2016.00140.
    1. Fujita M, Imadome K, Shoji Y, Isozaki T, Endo S, Yamada S, Imai T. Carbon-ion irradiation suppresses migration and invasiveness of human pancreatic carcinoma cells MIAPaCa-2 via Rac1 and RhoA degradation. Int J Radiat Oncol Biol Phys. 2015;93(1):173–180. doi: 10.1016/j.ijrobp.2015.05.009.
    1. Ando K, Fujita H, Hosoi A, Ma L, Wakatsuki M, Seino KI, Kakimi K, Imai T, Shimokawa T, Nakano T. Intravenous dendritic cell administration enhances suppression of lung metastasis induced by carbon-ion irradiation. J Radiat Res. 2017;58(4):446–455. doi: 10.1093/jrr/rrx005.
    1. Isaji S, Mizuno S, Windsor JA, Bassi C, Fernández-Del Castillo C, Hackert T, Hayasaki A, Katz MHG, Kim SW, Kishiwada M, Kitagawa H, Michalski CW, Wolfgang CL. International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017. Pancreatology. 2018;18(1):2–11. doi: 10.1016/j.pan.2017.11.011.
    1. US Department of Health and Human Services. Common terminology criteria for adverse events (CTCAE) version 4.02. May 28, 2009. CTCAE_4.02_2009-09-15_QuickReference_8.5x11.pdf. Accessed 21 Mar 2015.
    1. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205–213. doi: 10.1097/.
    1. Tempero Margaret A., Malafa Mokenge P., Al-Hawary Mahmoud, Asbun Horacio, Bain Andrew, Behrman Stephen W., Benson Al B., Binder Ellen, Cardin Dana B., Cha Charles, Chiorean E. Gabriela, Chung Vincent, Czito Brian, Dillhoff Mary, Dotan Efrat, Ferrone Cristina R., Hardacre Jeffrey, Hawkins William G., Herman Joseph, Ko Andrew H., Komanduri Srinadh, Koong Albert, LoConte Noelle, Lowy Andrew M., Moravek Cassadie, Nakakura Eric K., O'Reilly Eileen M., Obando Jorge, Reddy Sushanth, Scaife Courtney, Thayer Sarah, Weekes Colin D., Wolff Robert A., Wolpin Brian M., Burns Jennifer, Darlow Susan. Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network. 2017;15(8):1028–1061. doi: 10.6004/jnccn.2017.0131.
    1. Meschini G, Seregni M, Pella A, Ciocca M, Fossati P, Valvo F, Riboldi M, Baroni G. Evaluation of residual abdominal tumour motion in carbon ion gatedtreatments through respiratory motion modelling. Phys Med. 2017;34:28–37. doi: 10.1016/j.ejmp.2017.01.009.
    1. Ciocca M, Mirandola A, Molinelli S, Russo S, Mastella E, Vai A, Mairani A, Magro G, Pella A, Donetti M, Valvo F, Fossati P, Baroni G. Commissioning of the 4-D treatment delivery system for organ motion management in synchrotron-based scanning ion beams. Phys Med. 2016;32(12):1667–1671. doi: 10.1016/j.ejmp.2016.11.107.
    1. Kawarada Y. New classification of pancreatic carcinoma--Japan pancreas society. Nihon Shokakibyo Gakkai Zasshi. 2003;100(8):974–980.
    1. Evans DB, Rich TA, Byrd DR, et al. Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg. 1992;127:1335–1339. doi: 10.1001/archsurg.1992.01420110083017.
    1. Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, Schramm H, Fahlke J, Zuelke C, Burkart C, Gutberlet K, Kettner E, Schmalenberg H, Weigang-Koehler K, Bechstein WO, Niedergethmann M, Schmidt-Wolf I, Roll L, Doerken B, Riess H. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007;297(3):267–277. doi: 10.1001/jama.297.3.267.
    1. Oettle H, Neuhaus P, Hochhaus A, Hartmann JT, Gellert K, Ridwelski K, Niedergethmann M, Zülke C, Fahlke J, Arning MB, Sinn M, Hinke A, Riess H. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA. 2013;310(14):1473–1481. doi: 10.1001/jama.2013.279201.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する